Clinical trials: Dalteparin
Pulmonary Embolism
Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.
This prospective, multicenter, multinational, phase IV, interventional single-armed (management) trial will focus on the safety, efficacy and cost-effectiveness of a new oral anticoagulant in the treatment of patients with acute…
- Trial name
- PEITHO-2 (NCT02596555)
- Testing
- Dabigatran
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Prof. Stavros Konstantinides, MD
Thrombosis, Thromboembolism
Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study)
The purpose of this study is to assess the long-term treatment of patients with proximal venous thrombosis through the administration of subcutaneous low-molecular-weight heparin (tinzaparin sodium) versus the standard care use…
- Conditions
- Thrombosis, Thromboembolism, Venous Thrombosis
- Trial name
- NCT00203580
- Testing
- Tinzaparin sodium
- Where
- Canada
- Volunteers
- 910 people
- Sponsor
- University of Calgary
Hip and Knee Prosthesis Implantation
Aspirin Thromboprophylaxis After First-line Total Hip and Knee Replacement
Annually, more than 100,000 total hip prostheses (THA) and more than 100,000 total knee prostheses (TKA) are implanted for osteoarthritis in France, and these figures are set to increase significantly in the future as in all…
- Trial name
- TBP-ASPIR (NCT05128214)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Obesity, Obesity, Morbid
Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis
Pregnant and recently postpartum women are at significantly higher risk of developing a blood clot in their arms or legs known as a deep venous thrombosis (DVT) and/or a blood clot in their lungs known as a pulmonary embolism…
- Conditions
- Obesity, Obesity, Morbid, Pregnancy, Complications; Cesarean Section
- Trial name
- NCT02070237
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- MemorialCare Health System
Coronary Disease
Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease
Anticoagulation with heparin is indicated in several situations, such as acute coronary disease (in combination with antiplatelet therapy) for the prevention and treatment of venous thromboembolism and situations with high risk…
- Trial name
- NCT02389582
- Testing
- Dabigatran, Enoxaparin
- Where
- Brazil
- Volunteers
- 29 people
- Sponsor
- University of Sao Paulo General Hospital
Venous Thromboembolism
The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma
This study plans to learn more about how to prevent blood clots in the veins of your extremities. You are at risk of forming these clots after a major injury and when you have had surgery and are hospitalized on bed rest.
- Trial name
- VTEPX (NCT01050153)
- Testing
- Dalteparin sodium, Dalteparin sodium/aspirin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Denver Health and Hospital Authority
Embolism and Thrombosis
The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis
The purpose of this study is to obtain an estimate of catheter survival in the setting of upper extremity deep vein thrombosis (UEDVT) in patients treated with dalteparin and warfarin.
- Trial name
- NCT00216866
- Testing
- Dalteparin, Warfarin
- Where
- 6 sites in Canada
- Volunteers
- 70 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Thromboembolism
Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery
The aim of this study is to evaluate the feasibility of randomizing individuals to low molecular weight heparin (enoxaparin) or no treatment following cesarean delivery.
- Trial name
- NCT06118957
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- University of Utah
Arterial Occlusion
Effect of LOW-molecular-weight Heparin in Reducing Radial Artery Occlusion Rate After Transradial Coronary Catheterization
The purpose of the LOW-RAO study is to determine the most effective treatment for radial artery occlusion (RAO) after transradial coronary catheterization (both angiography and PCI).
- Trial name
- LOW-RAO (NCT04196309)
- Testing
- low molecular weight heparin
- Where
- Greece
- Volunteers
- 60 people
- Sponsor
- AHEPA University Hospital
Recurrent Miscarriage, Antiphospholipid Syndrome
Timing of Initiation of LMWH Administration in Pregnant Women With APS
Evaluation of the effect of altering the timing of initiation of low molecular weight heparin (LMWH) administration on the pregnancy outcomes in women with antiphospholipid syndrome (APS)
- Trial name
- NCT02326051
- Testing
- Enoxaparin
- Where
- 2 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Mohamed Sayed Abdelhafez
Bone Sarcoma, Femur Fracture
Dalteparin in Preventing DVT in Participants With Cancer
This trial studies how well dalteparin works in preventing deep vein thrombosis (DVT) (blood clots) in participants with cancer. Dalteparin is a blood thinner that can treat blood clots and may prevent them from forming.
- Conditions
- Bone Sarcoma, Femur Fracture, Lymphoma, Metastatic Neoplasm
- Trial name
- NCT00525057
- Testing
- Dalteparin
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Deep Venous Thrombosis
Low-Molecular-Weight Heparin (LMWH) for Deep Venous Thrombosis (DVT) Prophylaxis
1. The use of LMWH following open reduction and internal fixation of ankle fractures will reduce the number of thrombi formed. 2. The rates of clinically significant DVT will be equivalent between two groups.
- Trial name
- NCT01029821
- Testing
- Low-Molecular-Weight Heparin
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Tennessee
Factor V Leiden Heterozygous Mutation, Factor II Heterozygous Mutation
Evaluation of a Preventive Therapeutic Strategy for Postpartum Venous Thromboembolism in Women With Genetic Risk Factor
Background : pregnancy and postpartum period are times of increased risk for deep vein thrombosis (DVT). The incidence of venous thromboembolic disease (VTE) during pregnancy is estimated at 1-2 per 1,000, and this risk increases…
- Conditions
- Factor V Leiden Heterozygous Mutation, Factor II Heterozygous Mutation, Pregnancy, Postpartum
- Trial name
- POSTPART AS5-2 (NCT07342127)
- Testing
- Retrospective collection of health data, Phone call to every participant
- Where
- 2 sites in France
- Volunteers
- 86 people
- Sponsor
- Hospices Civils de Lyon
Arthritis, Osteoarthritis, Knee
Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement
The study will describe the short-term effects the study drug, rivaroxaban, has on the body when a patient is switched from enoxaparin injection (by needle) to oral rivaroxaban (by mouth) for the prevention of blood clotting in…
- Conditions
- Arthritis, Osteoarthritis, Knee, Osteoarthritis, Hip, Thromboembolism
- Trial name
- NCT01094886
- Testing
- Rivaroxaban
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Traumatic Injury, Venous Thromboembolism
Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients
This is a pilot study to determine if anti-thrombin III (AT-III) serum concentrations differ between patients with normal versus subtherapeutic anti-Xa trough concentrations when placed on enoxaparin 30 mg twice daily for VTE…
- Trial name
- NCT02412982
- Testing
- Enoxaparin 40 mg q12h, Enoxaparin 30 mg q8h
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- University of Cincinnati
Thromboembolism
A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients
This study is designed to provide efficacy and safety data for certoparin in the prophylaxis of venous thromboembolism in immobilized, acutely ill medical patients.
- Trial name
- NCT00451412
- Testing
- Certoparin, Unfractionated Heparin
- Where
- Germany
- Volunteers
- 3,254 people
- Sponsor
- Novartis
Acute Myocardial Infarction
Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction
The main objective is to compare a fibrinolytic strategy with an interventional strategy initiated as early as possible, preferably in the pre-hospital phase, with respect to resolution of ST-segment elevation at 120 minutes…
- Trial name
- SWEDES (NCT00806403)
- Testing
- reteplase 10+10 U, primary PCI
- Where
- 5 sites in Sweden
- Volunteers
- 205 people
- Sponsor
- Sahlgrenska University Hospital
Thromboembolism, Hemodialysis
A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery
The purpose of this study is to better understand if either dalteparin or tinzaparin is a better drug to use in dialysis patients on blood thinners who are at high risk of developing blood clots and need surgery.
- Trial name
- NCT00260988
- Testing
- Fragmin (dalteparin), Innohep (tinzaparin)
- Where
- 2 sites in Canada
- Volunteers
- 29 people
- Sponsor
- Ottawa Hospital Research Institute
Acute Kidney Injury, Renal Replacement Therapy
Efficacy, Safety and Pharmacokinetics of Tinzaparin During Slow Low Efficient Daily Dialysis in Intensive Care Patients
This study evaluates the pharmacokinetics of tinzaparin during renal replacement therapy (RRT). 60 patients with clinical indication for pharmacological thromboprophylaxis and slow low efficient daily dialysis (SLEDD) will be…
- Conditions
- Acute Kidney Injury, Renal Replacement Therapy, Anticoagulants
- Trial name
- Tinza-SLEDD (NCT03614741)
- Testing
- Tinzaparin continuous infusion, Tinzaparin bolus
- Where
- Finland
- Volunteers
- 60 people
- Sponsor
- Tampere University Hospital
Acute Coronary Syndrome
Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice
To collect data on safety and effectiveness of dalteparin in the management of non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without percutaneous corornary…
- Trial name
- NCT00922766
- Testing
- Dalteparin
- Where
- 24 sites in India
- Volunteers
- 618 people
- Sponsor
- Pfizer